SEED (Sustainable Entrepreneurship and Enterprise Development) Fund
C-CAMP has partnered with BIRAC to implement the Sustainable Entrepreneurship and Enterprise Development Fund (SEED Fund) with the aim of providing early stage and bridge funding to innovative technology driven life science start-ups.
The basic idea of SEED Fund is providing Capital assistance to startups with new and meritorious ideas, innovations and technologies. This would enable some of these start-ups to graduate to a level where they will be able to raise investments from angel/Venture capitalist or they will reach a position to seek loans from commercial banks /financial institutions. Thus the proposed seed support is positioned to act as a bridge between promoters’ investment and Venture/Angel investment.
- Equity based investment of up to 10% Equity stakes
- Investment of up to INR 30 Lakhs
Financial assistance for:
- Performing proof-of concept stage studies
- Prototype generation
- Scaling-up innovations
- Generating additional data or performing validation studies needed to secure next-level funding
- In selected cases, where funds can help with gap funding/next-level funding.
- Patent analysis, drafting and filing
- Market research analysis and Professional consultancy
- Enterprise building – Development of Market, Business Strategy, Business supply chain etc
- Indian Start-ups (registered under Companies Act, 2013), having at least 51% shareholders as Indian Citizens [does not include OCI or PIO] as the mandatory requirement)
- A company shall be considered as start up
- Up to 5 years from the date of its incorporation/registration
- If its turnover for any of the financial years has not exceeded Rs 25 cr, and
- If it is working towards innovation development, deployment or commercialization of new products, processes or services driven by technology or intellectual property
- The start-up should be working towards innovative technology/technologies and should be product oriented (not services oriented)
- The technology should be novel & there should be potential for generation of IP
- The technology should fulfill an unmet need and have an impact
- The start-ups should have a competent team in both technical & business aspects
- The technology should have a sound commercialization strategy and road map to the market
- The start-ups should have a clear understanding of the end-user/customer and market size
- The start-up should have a sound business plan and company vision
For any further information please contact funding at ccamp dot res dot in
Centre for Cellular And Molecular Platforms
NCBS-TIFR, GKVK, Bellary Road
Bangalore 560065, India
Shilps Sciences is a Bangalore-based start-up focused on harnessing the power of nanotechnology instruments to solve problems in healthcare. They are an developing Atomic Force Microscope and micro-fluidic technologies for isolating single cells for applications in Life Sciences. Shilps Sciences has developed a novel microfluidic technology to isolate and arrange cells. They are now combining this with an Atomic Force Microscope for cancer diagnostics. The company has created IP, built prototype demonstrators and is in an advanced stage of product development. They have ongoing collaborations with cancer labs.
Eyestem is a resident C-CAMP incubatee using stem cell and gene editing technologies to create breakthrough therapies for degenerative diseases of the eye. Age-related macular degeneration (AMD) affects the RPE layer of the retina and ranks third among the global causes of visual impairment. Eyestem’s vision is to create scalable and affordable stem cell therapy for these degenerative eye diseases. They have successfully grown retinal pigment epithelium and photoreceptors – two layers of the retina which are key for vision.
OCT therapies is a Mumbai-based company working on establishing a mesenchymal stem cell bank to treat burns and ulcers. Burns fatalities account for an estimated 1.63 lakhs annually in India. Wound infection, septicemia, wound contracture, scarring and ulcer leading to cancer are common complications. OCT Therapies proposes to use a cell based approach for wound healing in burns and chronic ulcers using allogenic Mesenchymal Stem Cells (WJ-MSCs). These cells can eventually be used for composite wound healing as an alternative to skin grafting. They are also developing stem cell based therapies for skin and hair regeneration. They recently launched their hair regeneration product.